Pharmacogenomic study of TPF regimen (combination chemotherapy of docetaxel, cisplatin, and 5-fluorouracil) in hypopharyngeal cancer
- Conditions
- Hypopharyngeal cancer
- Registration Number
- JPRN-UMIN000005628
- Lead Sponsor
- Department of Head and Neck Surgery, Saitama Medical University International Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 14
Not provided
Patients who did not meet the above mentioned inclusion criteria. 2) No distant metastases were existed when treatment was started. 3) Patients with severe hypersensitivities or drug allergy. 4) Patients with history of hypersensitivity reactions to polysorbate 80. 5) Patients with considerable cancerous body cavity fluid. 6) Patients with obvious infectious disease 7) Patients with watery diarrhea. 8) Patients with intestinal paralysis or obstruction. 9) Patients with severe aspiration, and high risk for aspiration pneumonia. 10) Patients with severe complications. (Examples: pulmonary fibrosis, interstitial pneumonia, tendency to bleed, active bleeding with necessity for frequent transfusion.) 11) Patients with peripheral (sensory or motor) neuropathy Grade 2 or greater. 12) Patients with edema Grade 2 or greater. 13) Patients with continuous administration of phenytoin, and warfarin potassium. 14) Patients with liver cirrhosis. 15) Patients with active double cancer. 16) Patients with uncontrollable diabetes 17) Patients with clinically serious cardiac disease. 18) Patients with clnically serious psycho-neurological disease for continuation therapy. 19) Patients who are pregnant or breast feeding or possibility of pregnancy 20) Patients whom investigators determined it impossible to complete the protocol treatment safely.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method